NewsRoom Articles

WednesdayApr 30, 2025 10:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments. Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors. Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by…

TuesdayApr 29, 2025 10:00 am

America to Slap 3,521% Tariff on Solar Energy Panels Made in Southeast Asia

The United States government is taking steps to protect its domestic solar equipment industry from being overwhelmed by major players from East Asia. Over the past decade, countries in East Asia have significantly boosted solar panel output, becoming some of the largest producers in the world. With the U.S. planning a major transition to renewables, their dominance threatens the survival of America's domestic solar industry. As a response, the U.S. Commerce Department has announced plans to impose import tariffs reaching a maximum of 3,521% on all solar panels originating from four Southeast Asian countries. The announcement follows a year-long investigation…

TuesdayApr 29, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…

MondayApr 28, 2025 10:00 am

India Unveils First System Leveraging Quantum Computing

An Indian tech startup with the government's backing has unveiled the first full-stack quantum computing system in India, marking a significant moment in the nation's advanced research and deep-tech journey and bringing the rapidly expanding Asian economy a step closer to achieving technological self-reliance. During the recent World Quantum Day, Bengaluru-based startup QpiAI introduced QpiAI-Indus, a quantum computer with no equals in India, and propelled the country to the top echelons of quantum computing research. Currently the most powerful quantum computing system in the country, QpiAI-Indus was developed under a government initiative dubbed the National Quantum Mission (NQM), which has…

FridayApr 25, 2025 11:15 am

D-Wave Quantum Inc. (NYSE: QBTS) and Japan Tobacco Complete Quantum AI Project Designed to Improve Drug Discovery Outcomes

D-Wave and Japan Tobacco’s pharmaceutical division completed a proof-of-concept project aimed at speeding up and improving the design of small molecule pharmaceuticals. D-Wave’s annealing quantum computer was used to train large language models within Japan Tobacco’s AI framework. The quantum-hybrid application outperformed classical methods in generating valid and drug-like molecules. Japan Tobacco plans to further pursue Quantum AI in molecular design following these early results. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”), have announced the successful completion of a proof-of-concept project applying quantum computing…

ThursdayApr 24, 2025 11:15 am

Zacks Initiates Coverage on SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2)

Despite policy uncertainty, demand for scalable solar and storage solutions in North America remains strong, especially in commercial and community sectors, the Zacks report says. The company has a development pipeline exceeding 1 GW and is aiming to triple its owned capacity in the next two years. SolarBank is expanding from solar EPC services into independent power production (“IPP”) and battery energy storage systems (“BESS”). Disseminated on behalf of SolarBank Corporation Zacks Small-Cap Research has launched coverage of SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and…

WednesdayApr 23, 2025 10:00 am

Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers

Researchers at Ohio State University Medical Center have identified a key enzyme that may be used to combat one of the deadliest types of brain cancer. Known as PGM3, this enzyme plays a critical role in the hexosamine biosynthesis pathway, which contributes to rapid tumor growth through protein and lipid glycosylation. Targeting PGM3 could significantly improve glioblastoma treatment outcomes. Glioblastomas are highly malignant tumors that typically form in the brain or spinal cord. They spread rapidly from their onset, causing increased intracranial pressure and symptoms such as headaches, nausea, drowsiness, blurred vision, seizures, and personality changes. These tumors are particularly…

TuesdayApr 22, 2025 10:30 am

Ford Otosan Deploys Vehicle Manufacturing Application Built with D-Wave Quantum Inc.’s (NYSE: QBTS) Technology

Ford Otosan has deployed into production a hybrid-quantum application to optimize production sequencing for its highly customizable Ford Transit vehicles. The application, developed with D-Wave’s annealing quantum computing technology, reduces scheduling time by over 80%. Ford Otosan is using the quantum optimization solution to help manage vehicle variability, labor constraints, and shop-floor dependencies more effectively than by using just classical computing approaches. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced that its technology is being deployed in a live manufacturing environment at Ford Otosan’s production facility in Turkey. The hybrid-quantum application is…

MondayApr 21, 2025 1:45 pm

D-Wave Quantum Inc. (NYSE: QBTS) Expands Quantum Optimization Offerings to Accelerate Commercial Adoption

At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables and aims to broaden its commercial use cases and increase adoption of its quantum optimization technology. The company is seeing increased interest from customers, independent software vendors, system integrators, and resellers and has revealed new quantum optimization use cases including portfolio optimization, offer allocation, and maintenance repair operations. Companies such as NTT DOCOMO and Ford Otosan are already deploying D-Wave’s quantum optimization technology in production environments. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced an expanded…

MondayApr 21, 2025 10:00 am

Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer

Portuguese researchers working to advance colorectal cancer treatment have discovered a new type of white blood cell that could open the door to more effective forms of immunotherapy. The white blood cells’ robust tumor cell identification and eradication abilities could enable researchers to develop a novel immunotherapy to combat colorectal cancer, currently the second most common type of cancer in Portugal and the third most commonly diagnosed cancer worldwide. The research was led by Gulbenkian Institute of Molecular Medicine (GIMM) Foundation lead investigator Bruno Silva-Santos and researcher Sofia Mensurado, who demonstrated that this new cell therapy is more effective at…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000